ALB and glioblastoma: In vivo studies with doxorubicin derivative DOXO-EMCH, which binds to the Cys34 position of human serum albumin (Aldoxo-HSA), circumventing systemic toxicity (Kratz et al., 2000), demonstrated superior response against GBM tumors in mice when compared to free Dox treatment.